CN102885919A - Preparation of slimming drug - Google Patents
Preparation of slimming drug Download PDFInfo
- Publication number
- CN102885919A CN102885919A CN2011102007798A CN201110200779A CN102885919A CN 102885919 A CN102885919 A CN 102885919A CN 2011102007798 A CN2011102007798 A CN 2011102007798A CN 201110200779 A CN201110200779 A CN 201110200779A CN 102885919 A CN102885919 A CN 102885919A
- Authority
- CN
- China
- Prior art keywords
- preparation
- semen
- medicine
- rhizoma
- chinese medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 95
- 238000002360 preparation method Methods 0.000 title claims abstract description 38
- 229940079593 drug Drugs 0.000 title claims abstract description 28
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 133
- 210000000582 semen Anatomy 0.000 claims abstract description 72
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 30
- 239000002994 raw material Substances 0.000 claims abstract description 26
- 239000013543 active substance Substances 0.000 claims abstract description 23
- 238000000034 method Methods 0.000 claims abstract description 15
- 239000002244 precipitate Substances 0.000 claims abstract description 13
- 230000008569 process Effects 0.000 claims abstract description 6
- 244000037364 Cinnamomum aromaticum Species 0.000 claims abstract description 3
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims abstract description 3
- 239000007788 liquid Substances 0.000 claims description 20
- 244000113306 Monascus purpureus Species 0.000 claims description 18
- 235000002322 Monascus purpureus Nutrition 0.000 claims description 18
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 18
- 239000000463 material Substances 0.000 claims description 18
- 229940057059 monascus purpureus Drugs 0.000 claims description 18
- 239000000243 solution Substances 0.000 claims description 17
- 238000001556 precipitation Methods 0.000 claims description 16
- 239000000284 extract Substances 0.000 claims description 14
- 239000000843 powder Substances 0.000 claims description 12
- 102220099307 rs144750850 Human genes 0.000 claims description 12
- 238000003756 stirring Methods 0.000 claims description 12
- 239000006228 supernatant Substances 0.000 claims description 12
- 238000009835 boiling Methods 0.000 claims description 11
- 239000008187 granular material Substances 0.000 claims description 11
- 102000011759 adducin Human genes 0.000 claims description 10
- 108010076723 adducin Proteins 0.000 claims description 10
- 239000002552 dosage form Substances 0.000 claims description 9
- 238000002791 soaking Methods 0.000 claims description 9
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 239000002775 capsule Substances 0.000 claims description 6
- 239000006187 pill Substances 0.000 claims description 5
- 239000006196 drop Substances 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 3
- 239000007924 injection Substances 0.000 claims description 3
- 239000002674 ointment Substances 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 2
- 239000000829 suppository Substances 0.000 claims description 2
- MFYSUUPKMDJYPF-UHFFFAOYSA-N 2-[(4-methyl-2-nitrophenyl)diazenyl]-3-oxo-n-phenylbutanamide Chemical compound C=1C=CC=CC=1NC(=O)C(C(=O)C)N=NC1=CC=C(C)C=C1[N+]([O-])=O MFYSUUPKMDJYPF-UHFFFAOYSA-N 0.000 abstract 1
- 244000276331 Citrus maxima Species 0.000 abstract 1
- 235000001759 Citrus maxima Nutrition 0.000 abstract 1
- 244000247747 Coptis groenlandica Species 0.000 abstract 1
- 235000002991 Coptis groenlandica Nutrition 0.000 abstract 1
- 235000009917 Crataegus X brevipes Nutrition 0.000 abstract 1
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 abstract 1
- 235000009685 Crataegus X maligna Nutrition 0.000 abstract 1
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 abstract 1
- 235000009486 Crataegus bullatus Nutrition 0.000 abstract 1
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 abstract 1
- 235000009682 Crataegus limnophila Nutrition 0.000 abstract 1
- 235000004423 Crataegus monogyna Nutrition 0.000 abstract 1
- 240000000171 Crataegus monogyna Species 0.000 abstract 1
- 235000002313 Crataegus paludosa Nutrition 0.000 abstract 1
- 235000009840 Crataegus x incaedua Nutrition 0.000 abstract 1
- 235000003805 Musa ABB Group Nutrition 0.000 abstract 1
- 240000008790 Musa x paradisiaca Species 0.000 abstract 1
- 235000015266 Plantago major Nutrition 0.000 abstract 1
- 244000299790 Rheum rhabarbarum Species 0.000 abstract 1
- 235000009411 Rheum rhabarbarum Nutrition 0.000 abstract 1
- 241000219784 Sophora Species 0.000 abstract 1
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 abstract 1
- 230000001376 precipitating effect Effects 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 31
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 20
- 239000000203 mixture Substances 0.000 description 19
- 230000037396 body weight Effects 0.000 description 16
- 208000008589 Obesity Diseases 0.000 description 15
- 235000020824 obesity Nutrition 0.000 description 14
- 235000019197 fats Nutrition 0.000 description 13
- 239000003826 tablet Substances 0.000 description 13
- 239000000080 wetting agent Substances 0.000 description 11
- 229920002472 Starch Polymers 0.000 description 10
- 235000019359 magnesium stearate Nutrition 0.000 description 10
- 235000019698 starch Nutrition 0.000 description 10
- 239000008107 starch Substances 0.000 description 10
- 229940032147 starch Drugs 0.000 description 10
- 210000001789 adipocyte Anatomy 0.000 description 8
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 235000013305 food Nutrition 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 210000000577 adipose tissue Anatomy 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 101001130226 Homo sapiens Phosphatidylcholine-sterol acyltransferase Proteins 0.000 description 5
- 102000016267 Leptin Human genes 0.000 description 5
- 108010092277 Leptin Proteins 0.000 description 5
- 102100031538 Phosphatidylcholine-sterol acyltransferase Human genes 0.000 description 5
- 229930006000 Sucrose Natural products 0.000 description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 5
- 229940039781 leptin Drugs 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 230000001603 reducing effect Effects 0.000 description 5
- 239000005720 sucrose Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 210000004392 genitalia Anatomy 0.000 description 4
- 238000005469 granulation Methods 0.000 description 4
- 230000003179 granulation Effects 0.000 description 4
- 210000004013 groin Anatomy 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 230000009182 swimming Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 208000021017 Weight Gain Diseases 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000002421 anti-septic effect Effects 0.000 description 3
- 230000036528 appetite Effects 0.000 description 3
- 235000019789 appetite Nutrition 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 210000001596 intra-abdominal fat Anatomy 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- -1 sublimed preparation Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 235000019786 weight gain Nutrition 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 108010023302 HDL Cholesterol Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010020710 Hyperphagia Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 102100037205 Sal-like protein 2 Human genes 0.000 description 2
- 101710192308 Sal-like protein 2 Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000282894 Sus scrofa domesticus Species 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 210000002969 egg yolk Anatomy 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 235000013312 flour Nutrition 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 235000020830 overeating Nutrition 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000011552 rat model Methods 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 238000003809 water extraction Methods 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 235000008939 whole milk Nutrition 0.000 description 2
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Natural products OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 238000004378 air conditioning Methods 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
- 150000008041 alkali metal carbonates Chemical class 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- NKWPZUCBCARRDP-UHFFFAOYSA-L calcium bicarbonate Chemical compound [Ca+2].OC([O-])=O.OC([O-])=O NKWPZUCBCARRDP-UHFFFAOYSA-L 0.000 description 1
- 229910000020 calcium bicarbonate Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229960001305 cysteine hydrochloride Drugs 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- ACYGYJFTZSAZKR-UHFFFAOYSA-J dicalcium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Ca+2].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O ACYGYJFTZSAZKR-UHFFFAOYSA-J 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003337 fertilizer Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011167 hydrochloric acid Nutrition 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 210000004279 orbit Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 108700022737 rat Fat1 Proteins 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 150000003376 silicon Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 229940080313 sodium starch Drugs 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 239000002918 waste heat Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to preparation of a slimming drug which is prepared from the following Chinese medicine raw materials: raw rhubarb, ginger-processed coptis, raw hawthorn, fermentum rubrum, pummelo peel, lightyellow sophora root, rhizoma atractylodis, semen descurainiae, plantain seed and cassia seed. The preparation method comprises steps of decocting with water, precipitating with alcohol and using the precipitate as pharmaceutically active substances to process the medicinal preparation.
Description
Technical field:
The present invention relates to a kind of field of medicaments, especially relate to a kind of Chinese medicine preparation composition and method of making the same for fat-reducing.
Background technology:
Obesity (obesity) is a kind of chronic disease.Estimate that according to World Health Organization (WHO) it is human face at present the easiest to be out in the cold, but sickness rate is in a kind of disease that sharply rises.Except the mankind, many house pets also can suffer from obesity.Mammal (comprising the people) storage hyperliposis is to such an extent as to health is affected.
Obesity (obesity) is one group of common, ancient metabolism disease group.When human body feed heat during more than consumption of calorie, waste heat is stored in the body with fatty form, and its amount surpasses the normal physiological requirement, and then develops into obesity when reaching certain value.15%～18% of the about percentage of liveweight of Normal Male Adults fatty tissue weight, the women accounts for 20%～25%.With age growth, the corresponding increase of body fat proportion.Because making be above standard body weight 20% or Body Mass Index [BMI=body weight (Kg)/(height) 2 (m2)] of body weight, the increase of body fat is called obesity greater than 24.As can the person of seeking claiming simple obesity without the obvious cause of disease; Have clear and definite cause of disease person and be called secondary obesity.
History with traditional Chinese medicine capable of reducing weight is of long standing and well established in China, uses the story of Chinese medicine obesity when three states with regard to Huatuo on the books.Ancients' treatment by Chinese herbs obesity has a lot of different methods of weight-reducing, for example; Motherland's medical science sporadically appears in the successive dynasties to the understanding of obesity and does." the logical deficiency and excess opinion of commenting of Plain Questions " cloud: " fertile high official, then the disease of fat meat and fine grain also." " the strange sick opinion of Plain Questions " meaning: " this person must count the sweet and refreshing and many fertilizer of food also, overeating greasy food bringing about internal heat, over-eating the food with sweet flavor bringing about abdominal distension." but the dialectical Therapeutic Method of theory of Chinese medical science is constant its topic.That is exactly will be particular about " because body is controlled " according to the various different origins of disease: be exactly the various different origins according to obesity disease, open different prescriptions according to dissimilar systems.Here it is why traditional Chinese medicine capable of reducing weight why the reason of so magical curative effect is arranged.Traditional Chinese medicine capable of reducing weight is to control according to dialectical the executing of the different body constitution of slimmer according to the Chinese medical discrimination theory, suits the remedy to the case, and fundamentally solves problem of obesity.It is safer to compare Western medicine because of traditional Chinese medicine capable of reducing weight in addition, be free from side effects, and Western medicine contains various chemical analysis and the personage's that gradually lost weight repulsion comparatively speaking.
Weight-losing Chinese patent medicine in the market is few, and existing medicine belongs to a bit cures the symptoms, not the disease, and some uses expensive composition, and some is cut and interrupt using owing to uncertain therapeutic efficacy in application process.
The invention provides a kind of determined curative effect, safe ready, little, the cheap pure traditional Chinese compound medicine of side effect.
Summary of the invention:
The invention provides a kind of Chinese medicine preparation compositions for fat-reducing, said preparation is prepared from Radix Et Rhizoma Rhei, prepared RHIZOMA COPTIDIS with rhizoma zingiberis recens juice by following raw material of Chinese medicine medicine, Fructus Crataegi, Monas cuspurpureus Went, Exocarpium Citri Grandis, Radix Sophorae Flavescentis, Rhizoma Atractylodis, Semen Lepidii (Semen Descurainiae), Semen Plantaginis, Semen Cassiae, its preparation method is included as water and decocts, and with the alcohol precipitation, is processed into the step of pharmaceutical preparation with precipitation as pharmaceutically active substance.
Wherein the proportioning of each raw material of Chinese medicine medicine is as follows:
Radix Et Rhizoma Rhei 3-12 part prepared RHIZOMA COPTIDIS with rhizoma zingiberis recens juice 7.5-30 part Fructus Crataegi 7.5-30 part Monas cuspurpureus Went 3-12 part
Exocarpium Citri Grandis 7.5-30 part Radix Sophorae Flavescentis 7.5-30 part Rhizoma Atractylodis 7.5-30 part Semen Lepidii (Semen Descurainiae) 7.5-30 part
Semen Plantaginis 15-60 part Semen Cassiae 15-60 part.
The proportioning of preferred each raw material of Chinese medicine medicine is as follows:
Radix Et Rhizoma Rhei 4.5-8 part prepared RHIZOMA COPTIDIS with rhizoma zingiberis recens juice 11.25-20 part Fructus Crataegi 11.25-20 part Monas cuspurpureus Went 4.5-8 part
Exocarpium Citri Grandis 11.25-20 part Radix Sophorae Flavescentis 11.25-20 part Rhizoma Atractylodis 11.25-20 part Semen Lepidii (Semen Descurainiae) 11.25-20 part
Semen Plantaginis 22.5-40 part Semen Cassiae 22.5-40 part.
The proportioning of most preferred each raw material of Chinese medicine medicine is as follows:
15 parts of 6 parts of Exocarpium Citri Grandises of 15 parts of Monas cuspurpureus Went of 15 parts of Fructus Crataegi of 6 parts of prepared RHIZOMA COPTIDIS with rhizoma zingiberis recens juice of Radix Et Rhizoma Rhei
30 parts of 30 parts of Semen Cassiaes of 15 portions of Semen Plantaginiss of 15 parts of Semen Lepidii (Semen Descurainiae)s of 15 parts of Rhizoma Atractylodis of Radix Sophorae Flavescentis.
In more than forming, weight is calculated with crude drug, and part is weight portion, if in grams, more than composition can be made into a pharmaceutical preparation 5-50 preparation unit, and described preparation unit refers to, the final drug preparation of making, as make solid preparation 5-50 unit, oral liquid 5-50ml etc.
More than form the preparation that can be made into 1-6 taking dose, as tablet, make 18, each taking dose can be the 3-18 sheet, can take 1-6 time altogether.As granule, make 6 bags, each serving using the 1-2 bag, can take 3-6 time altogether.
More than form to be by weight as proportioning, when producing, can increase or reduce according to corresponding proportion, can be take kilogram as unit such as large-scale production, or take ton as unit, small-scale production also can be take milligram as unit, weight can increase or reduce, but the constant rate of the raw medicinal herbs weight proportion between each composition.
The ratio of above weight proportion obtains through science screening, for especial patient, and such as serious symptom or light disease, fat or modest patient, the proportioning of the amount that can corresponding adjustment forms increases or reduces being no more than 300%, and drug effect is constant.
Single medicinal material, especially ministerial drug and adjuvant drug in more than forming also can be replaced by the suitable Chinese medicine with identical property of medicine, and its drug effect of the Chinese medicine preparation after the replacement is constant.
Chinese medicine composition of the present invention is to process through extraction or other modes by the raw material of Chinese medicine that above-mentioned prescription is formed, and makes pharmaceutically active substance, subsequently, take this material as raw material, add the medicine acceptable carrier when needing, make according to the routine techniques of galenic pharmacy.
Pharmaceutically active substance in the Chinese medicine composition of the present invention, its shared percentage by weight in preparation can be 0.1-99.9%, all the other are the medicine acceptable carrier.Pharmaceutical composition of the present invention exists with unit dosage form, and described unit dosage form refers to the unit of preparation, such as every of tablet, and every capsules of capsule, every bottle of oral liquid, every bag of granule etc.
Chinese medicine composition of the present invention can be any pharmaceutically useful dosage form, and these dosage forms comprise: tablet, capsule, oral liquid, suck agent, granule, pill, powder, unguentum, sublimed preparation, suspensoid, powder, injection, suppository, drop pill, spray, drop, patch.
Chinese medicine composition of the present invention, peroral dosage form preferably, as: capsule, tablet, oral liquid, granule, pill, powder, sublimed preparation, unguentum etc.
Chinese medicine composition of the present invention, the preparation of its oral administration can contain excipient commonly used, such as binding agent, filler, diluent, tablet agent, lubricant, disintegrating agent, coloring agent, flavoring agent and wetting agent, can carry out coating to tablet in case of necessity.
Applicable filler comprises cellulose, mannitol, lactose and other similar filler.Suitable disintegrating agent comprises starch, polyvinylpyrrolidone and starch derivatives, for example sodium starch glycollate.Suitable lubricant comprises, for example magnesium stearate.The suitable acceptable wetting agent of medicine comprises sodium lauryl sulphate.
Can fill by mixing, the method that tabletting etc. are commonly used prepares solid oral composition.Repeatedly mix active substance is distributed in those compositionss of a large amount of filleies of whole use.
The form of oral liquid for example can be aqueous or oily suspensions, solution, Emulsion, syrup or elixir, perhaps can be a kind of before use available water or other suitable composite dry products of carrier.This liquid preparation can contain conventional additive, such as suspending agent, for example sorbitol, syrup, methylcellulose, gelatin, hydroxyethyl-cellulose, carboxymethyl cellulose, aluminium stearate gel or hydrogenation edible fat, emulsifying agent, for example lecithin, anhydro sorbitol monooleate or arabic gum; Non-aqueous carrier (they can comprise edible oil), for example almond oil, fractionated coconut oil, such as oily ester, propylene glycol or the ethanol of the ester of glycerol; Antiseptic, for example para hydroxybenzene methyl ester or propyl p-hydroxybenzoate or sorbic acid, and if necessary, can contain conventional flavouring agent or coloring agent.
For injection, the liquid unit dosage forms of preparation contains active substance of the present invention and sterile carrier.According to carrier and concentration, this chemical compound can be suspended or dissolving.The preparation of solution is normally by being dissolved in active substance in a kind of carrier filter-sterilized before it is packed into a kind of suitable bottle or ampoule, then sealing.Adjuvant for example a kind of local anesthetic, antiseptic and buffer agent also can be dissolved in this carrier.In order to improve its stability, can be after the bottle of packing into that this compositions is freezing, and under vacuum, water is removed.
Chinese medicine composition of the present invention, when being prepared into medicament, optionally add suitable medicine acceptable carrier, described medicine acceptable carrier is selected from: mannitol, sorbitol, sodium pyrosulfite, sodium sulfite, sodium thiosulfate, cysteine hydrochloride, TGA, methionine, vitamin C, EDETATE SODIUM, Ethylenediaminetetraacetic Acid Calcium Salt, the alkali-metal carbonate of monovalence, acetate, phosphate or its aqueous solution, hydrochloric acid, acetic acid, sulphuric acid, phosphoric acid, aminoacid, sodium chloride, potassium chloride, sodium lactate, xylitol, maltose, glucose, fructose, dextran, glycine, starch, sucrose, lactose, mannitol, silicon derivative, cellulose and derivant thereof, alginate, gelatin, polyvinylpyrrolidone, glycerol, POLYSORBATE 80, agar, calcium carbonate, calcium bicarbonate, surfactant, Polyethylene Glycol, cyclodextrin, beta-schardinger dextrin-, the phospholipid material, Kaolin, Pulvis Talci, calcium stearate, magnesium stearate etc.
Chinese medicine composition of the present invention is determined usage and dosage according to patient's situation in use, but takes every day three times, each 1-20 agent, as: 1-20 bag or grain or sheet.
Chinese medicine composition of the present invention can be standby in order to the below legal system:
The crude drug water extraction obtains water extract, and water extract is precipitated with the alcohol precipitation and is pharmaceutically active substance, further is processed into pharmaceutical preparation.
Crude drug decocts with water 1-5 time, each 1-4 hour, amount of water is that doubly (1 raw material w: water 3-10v), decoction liquor is filtered, and medicinal residues discard for the 3-10 of crude drug weight, concentrated, add alcohol and make precipitation, the ethanol that preferred 90% (v/v) of ethanol is above, preferred 95% ethanol, the amount that adds ethanol is to make the concentration of alcoholic solution reach 70-80%, preferred 75% (v/v); Filter to get precipitation, namely get pharmaceutically active substance, subsequently, take this material as raw material, add the medicine acceptable carrier when needing, make pharmaceutical preparation according to the routine techniques of galenic pharmacy.
Most preferred method is as follows:
Crude drug adds 10 times of water soaking 0.5h, be heated to boiling after, extract 1h, filter, medicinal residues add 8 times of decoctings and boil 1h, filter, medicinal residues discard, extracted twice liquid is merged, and 60～65 ℃ are evaporated to D60=1.05-1.10, get concentrated solution, after being cooled to room temperature, add 95% ethanol precipitate with ethanol, the limit edged stirs, and contains alcohol 75% to supernatant, leave standstill 12h, filter, the precipitation oven dry namely gets pharmaceutically active substance, subsequently, take this material as raw material, add the medicine acceptable carrier when needing, make pharmaceutical preparation according to the routine techniques of galenic pharmacy.
Chinese medicine composition of the present invention has following [function cures mainly]: disappear cream the turbid descending, activating QI to eliminate phlegm, and to regulate blood fat as main, take blood sugar lowering, blood pressure lowering as auxiliary, across-the-board regulation organism metabolism system.
Below further specify beneficial effect of the present invention by [test of pesticide effectiveness]:
Test objective
By adopting the obese rat model, observe the sample of medicine different process of the present invention to the preventive and therapeutic effect of Obesity of Rats, provide experimental basis for selecting from now on suitable process exploitation appetrol.
Experiment material
1, be subjected to reagent:
CT-4:15.19g crude drug/g powder, dosage are 16g crude drug/kg;
Provided by sky Shi Li Pharmacy stock Co., Ltd.
2, nutrient fodder prescription: normal feedstuff 50%, Adeps Sus domestica 12%, sucrose 12%, yolk powder 3%, analysis for soybean powder 4%, flour 15%, Sal 2%, whole milk powder 2%
3, medicine preparation:
All taken by weighing in right amount by reagent, grind with distilled water respectively and be made into desired concn, for animal gastric infusion, administration volume: 10ml/kg body weight
Administration number of times: every day gastric infusion once.
4, reagent:
TG: lot number: 090401, Beijing Zhongsheng Beikong Biological Science ﹠ Technology Co., Ltd..
TCHO: lot number: 090611, Beijing Zhongsheng Beikong Biological Science ﹠ Technology Co., Ltd..
ALB: lot number: 090241, Beijing Zhongsheng Beikong Biological Science ﹠ Technology Co., Ltd..
TP: lot number: 090821, Beijing Zhongsheng Beikong Biological Science ﹠ Technology Co., Ltd..
HDL-C: lot number: 090751, Beijing Zhongsheng Beikong Biological Science ﹠ Technology Co., Ltd..
Leptin: lot number 327MO3728250, ADL company produces
LCAT: lot number 417MO5629150, ADL company produces
Laboratory animal
The SD rat, the SPF level, male, body weight 45-55g during introduction.The red Animal Science company limited in mountains and rivers, Tianjin provides, production licence numbering: SCXK (Tianjin) 2009-0001, the Quality of Experimental Animals quality certification number: 0002518.
Raising is having in the observation ward of central air-conditioning (accurate No. 012 of the real facility in Tianjin meets the barrier grade standard), and rat feed drinks pure water for the flourish Animal Science company limited of Tianjin China provides.
Experimental apparatus
The large capacity Multi-pipe centrifugal of LXJ-II Type B low speed machine, Town in Shanghai booth scientific instrument company limited.
XW-80A vortex instrument: Shanghai Hu Xi analytical tool Co., Ltd., Factory.
DK type electric-heated thermostatic water bath: the upper grand experimental facilities company limited of Nereid.
The SUNRISE microplate reader: Austria rises day.
PL203 electronic balance: Mettler-Toledo Instrument (Shanghai) Co., Ltd..
T5000 electronic balance: two outstanding brother's (group) company limiteies of the U.S..
Hitachi's 7080 type full automatic biochemical apparatus: FDAC Co., Ltd..
Test method and result
1. test method:
150 of male SD rats, body weight 45g-55g, observation ward raised 3 days, at random rat is divided into 10 of 140 of model group and Normal groups, modeling group rat feeding nutrient fodder (normal feedstuff 50%, Adeps Sus domestica 12%, sucrose 12%, yolk powder 3%, analysis for soybean powder 4%, flour 15%, Sal 2%, whole milk powder 2%), after continuously feeding for 6 weeks, choose body weight and exceed the Normal group average weight, totally 100 as qualified obese rat model.
Select 30 of qualified obese rats, by the body weight level, stratified random is divided into 3 groups, and 10 every group, be respectively: model control group gavages distilled water; The CT-4 group gavages drug suspension of the present invention (according to the preparation of embodiment 1 method), and dosage sees Table 1; 10 of Normal groups gavage pure water.Every day, ig was 1 time, 4 weeks of successive administration.Observe the animal state at duration of test, the rat food ration, feces is done rare degree etc., weigh in weekly and appetite once, the 3rd all eye sockets after the treatment are got blood 2ml, 3000 rev/mins centrifugal, get serum, detect TG, TCHO, TP, ALB, HDL-C content, leptin and LCAT are active, when experimental period, finish (after 4 weeks of administration), rat is put into frozen water, can not float the water surface in observation and the record rat head sinking 5s and be the rats'swimming time-to-live, behind the rats death, measure and respectively organize rat body long (nose is to the length of anus), and calculating Lee ' s index [Lee ' s index=(body weight
1/3* 1000)/body long (cm)], cut open and get groin, the kidney whole fatty tissuees of intraperitoneal on every side, take by weighing respectively weight in wet base; And same position is fatty around getting genitals, and 12% formalin solution is fixed, and tissue pathological slice is done in HE dyeing, under 200 times of mirrors, counts adipose cell number in the full visual field, gets the average in 5 visuals field.
Continuous data represents that with average and standard deviation statistical procedures is the t check.
2. result of the test:
2.1 the impact on obese rat general status, body weight and appetite
At duration of test, each organizes the rat mental status, Excreta normal, have no loose stool, compare with Normal group, the body weight of model group rat (seeing Table 1), body weight gain rate (seeing Table 2), food ration (seeing Table 3) all have significant difference, compare with the model group rat, each group body weight gains after 2 weeks of administration obviously reduce.Though each dosage group food ration and model group relatively reduce without significance after the 2nd week, all are less than model group, point out medicine of the present invention to alleviate rat body weight and may reduce relevant with its food ration.
Table 1. is on the impact of obese rat body weight
Compare with Normal group
△ △P＜0.01
△ △ △P＜0.001
Administration group and model group are relatively
*P＜0.05
*P＜0.01
* *P＜0.001
Table 2. is on the impact of obese rat body weight gain rate
Compare with Normal group
△P＜0.05
△ △P＜0.01
△ △ △P＜0.001
Administration group and model group are relatively
*P＜0.05
*P＜0.01
* *P＜0.001
Table 3. is on the impact of obese rat appetite
Compare with Normal group
△ △P＜0.01
△ △ △P＜0.001
Administration group and model group are relatively
*P＜0.05
*P＜0.01
* *P＜0.001
2.2. on blood fat, total protein and albuminous impact in the rat blood serum
Result's (seeing Table 4) shows, compares with Normal group, and model group Serum TC HO content significantly raises; Compare with model group, each sample has no reducing effect to blood fat.
Table 4. is on blood fat, total protein and albuminous impact in the rat blood serum
Compare with Normal group
△ △P＜0.01
△ △ △P＜0.001
Administration group and model group are relatively
*P＜0.05
*P＜0.01
* *P＜0.001
2.3. the impact on leptin in the rat blood serum and LCAT
Result's (seeing Table 5) shows, compares with Normal group, and model group serum leptin and LCAT activity have no significant change.
Table 5. is on the impact of leptin in the rat blood serum and LCAT
2.4. on reaching the impact of intra abdominal fat weight in wet base and fat coefficient around groin, the kidney
Result's (seeing Table 6) shows, compares with Normal group, and model group rat groin, kidney reach intra abdominal fat weight in wet base and fat coefficient on every side and significantly raise, and compares with model group, and sample all can obviously reduce the accumulation of body fat.
Table 6 is on reaching the impact of intra abdominal fat weight in wet base and fat coefficient around groin, the kidney
Compare with Normal group
△P＜0.05
△ △P＜0.01 administration group and model group are relatively
*P＜0.05
*P＜0.01
* *P＜0.001
2.5 the impact on Lee ' s exponential sum swimming time
Result's (seeing Table 7) shows, compares with Normal group, and model group rat Lee ' s index significantly raises, and compares with model group, and sample has no significant effect Lee ' s index.Model group and Normal group relatively swimming time prolong, and sample and model group be no significant difference relatively, can't reduce its exercise tolerance when showing drug sample fat-reducing of the present invention.
Table 7. is on the impact of Lee ' s exponential sum swimming time
Compare with Normal group
△P＜0.05
Administration group and model group are relatively
*P＜0.05
2.6 the impact on adipose cell form and adipose cell quantity
The result (see Table 8, Fig. 1-Fig. 3) show, with Normal group relatively, model group rat fat cell number obviously reduces, adipose cell is loose; Compare with model group, sample can obviously increase the adipose cell number.Show that medicine CT-4 sample of the present invention can increase obese rat body fat number of cells, diminishes adipose cell.
Table 8. is on the impact of adipose cell quantity
Compare with Normal group
△ △ △P＜0.01
Administration group and model group are relatively
*P＜0.05
*P＜0.01
* *P＜0.001
Composition stable of the present invention is good, few side effects, long shelf-life, the characteristics such as therapeutic effect is remarkable.Simultaneously, preparation method of the present invention is simple, is fit to production, and extraction ratio is high; Composition prescription is conventional Chinese medicine in this invention, avoids the use of rare Chinese medicine and animal drugs, has reduced production cost, benefits extensive patients, is fit to promote.
Description of drawings:
Fat around Fig. 1 matched group SD rat genitals
Fat around Fig. 2 model group SD rat genitals
Fat around Fig. 3 CT-4 group SD rat genitals
The specific embodiment:
Only being to explain content of the present invention by following specific embodiment, is not the further restriction to protection domain of the present invention.
Embodiment 1
Radix Et Rhizoma Rhei 6g prepared RHIZOMA COPTIDIS with rhizoma zingiberis recens juice 15g Fructus Crataegi 15g Monas cuspurpureus Went 6g Exocarpium Citri Grandis 15g
Radix Sophorae Flavescentis 15g Rhizoma Atractylodis 15g Semen Lepidii (Semen Descurainiae) 15g Semen Plantaginis 30g Semen Cassiae 30g
Crude drug adds 10 times of water soaking 0.5h, be heated to boiling after, extract 1h, filter, medicinal residues add 8 times of decoctings and boil 1h, filter, medicinal residues discard, and extracted twice liquid is merged, and 60～65 ℃ are evaporated to D60=1.05-1.10, concentrated solution, be cooled to room temperature after, add 95% ethanol precipitate with ethanol, the limit edged stirs, and contains alcohol 75% to supernatant, leaves standstill 12h, filter, the precipitation oven dry namely gets pharmaceutically active substance, subsequently, take this material as raw material, granulate with starch is mixed, make wetting agent with 95% ethanol, add an amount of magnesium stearate, tabletting obtains tablet.
Embodiment 2
Radix Et Rhizoma Rhei 3g prepared RHIZOMA COPTIDIS with rhizoma zingiberis recens juice 7.5g Fructus Crataegi 7.5g Monas cuspurpureus Went 3g
Exocarpium Citri Grandis 7.5g Radix Sophorae Flavescentis 7.5g Rhizoma Atractylodis 7.5g Semen Lepidii (Semen Descurainiae) 7.5g
Semen Plantaginis 15g Semen Cassiae 15g
Crude drug adds 10 times of water soaking 0.5h, be heated to boiling after, extract 1h, filter, medicinal residues add 8 times of decoctings and boil 1h, filter, medicinal residues discard, and extracted twice liquid is merged, and 60～65 ℃ are evaporated to D60=1.05-1.10, concentrated solution, be cooled to room temperature after, add 95% ethanol precipitate with ethanol, the limit edged stirs, and contains alcohol 75% to supernatant, leaves standstill 12h, filter, the precipitation oven dry namely gets pharmaceutically active substance, subsequently, take this material as raw material, granulate with starch is mixed, make wetting agent with 95% ethanol, add an amount of magnesium stearate, tabletting obtains tablet.
Embodiment 3
Radix Et Rhizoma Rhei 12g prepared RHIZOMA COPTIDIS with rhizoma zingiberis recens juice 30g Fructus Crataegi 30g Monas cuspurpureus Went 12g
Exocarpium Citri Grandis 30g Radix Sophorae Flavescentis 30g Rhizoma Atractylodis 30g Semen Lepidii (Semen Descurainiae) 30g
Semen Plantaginis 60g Semen Cassiae 60g
Crude drug adds 10 times of water soaking 0.5h, be heated to boiling after, extract 1h, filter, medicinal residues add 8 times of decoctings and boil 1h, filter, medicinal residues discard, and extracted twice liquid is merged, and 60～65 ℃ are evaporated to D60=1.05-1.10, concentrated solution, be cooled to room temperature after, add 95% ethanol precipitate with ethanol, the limit edged stirs, contain alcohol 75% to supernatant, leave standstill 12h, filter, the precipitation oven dry, namely get pharmaceutically active substance, subsequently, take this material as raw material, granulate with starch is mixed, ethanol with 95% is made wetting agent, adds an amount of magnesium stearate, incapsulates and obtains capsule.
Embodiment 4
Radix Et Rhizoma Rhei 8g prepared RHIZOMA COPTIDIS with rhizoma zingiberis recens juice 20g Fructus Crataegi 20g Monas cuspurpureus Went 8g
Exocarpium Citri Grandis 20g Radix Sophorae Flavescentis 20g Rhizoma Atractylodis 20g Semen Lepidii (Semen Descurainiae) 20g
Front sub-40g Semen Cassiae 40g
Crude drug adds 10 times of water soaking 0.5h, be heated to boiling after, extract 1h, filter, medicinal residues add 8 times of decoctings and boil 1h, filter, medicinal residues discard, and extracted twice liquid is merged, and 60～65 ℃ are evaporated to D60=1.05-1.10, concentrated solution, be cooled to room temperature after, add 95% ethanol precipitate with ethanol, the limit edged stirs, and contains alcohol 75% to supernatant, leaves standstill 12h, filter, the precipitation oven dry namely gets pharmaceutically active substance, subsequently, take this material as raw material, and soluble dextrins, sucrose is mixed granulates, and makes wetting agent with 95% ethanol, add an amount of Pulvis Talci, be packaged to be granule.
Embodiment 5
Radix Et Rhizoma Rhei 4.5g prepared RHIZOMA COPTIDIS with rhizoma zingiberis recens juice 11.25g Fructus Crataegi 11.25g Monas cuspurpureus Went 4.5g
Exocarpium Citri Grandis 11.25g Radix Sophorae Flavescentis 11.25g Rhizoma Atractylodis 11.25g Semen Lepidii (Semen Descurainiae) 11.25g
Semen Plantaginis 22.5g Semen Cassiae 22.5g
Crude drug adds 10 times of water soaking 0.5h, be heated to boiling after, extract 1h, filter, medicinal residues add 8 times of decoctings and boil 1h, filter, medicinal residues discard, and extracted twice liquid is merged, and 60～65 ℃ are evaporated to D60=1.05-1.10, concentrated solution, be cooled to room temperature after, add 95% ethanol precipitate with ethanol, the limit edged stirs, and contains alcohol 75% to supernatant, leaves standstill 12h, filter, the precipitation oven dry namely gets pharmaceutically active substance, subsequently, take this material as raw material, add sucrose, ethanol, antiseptic, essence, water is modulated into oral liquid, and packing gets final product.
Embodiment 6
Radix Et Rhizoma Rhei 6g prepared RHIZOMA COPTIDIS with rhizoma zingiberis recens juice 15g Fructus Crataegi 15g Monas cuspurpureus Went 6g Exocarpium Citri Grandis 15g
Radix Sophorae Flavescentis 15g Rhizoma Atractylodis 15g Semen Lepidii (Semen Descurainiae) 15g Semen Plantaginis 30g Semen Cassiae 30g
Crude drug adds 10 times of decoctings and boils, and extracts 1h, filters, medicinal residues add 10 times of decoctings and boil 1h, filter, and medicinal residues discard, extracted twice liquid is merged, and 60～65 ℃ are evaporated to D60=1.05-1.10, get concentrated solution, after being cooled to room temperature, add 100% ethanol precipitate with ethanol, the limit edged stirs, to supernatant contain alcohol 80%, leave standstill 12h, filter, be precipitated, namely get pharmaceutically active substance, subsequently, take this material as raw material, and the mixed granulation of starch, ethanol with 95% is made wetting agent, add an amount of magnesium stearate, tabletting obtains tablet.
Embodiment 7
Radix Et Rhizoma Rhei 3g prepared RHIZOMA COPTIDIS with rhizoma zingiberis recens juice 7.5g Fructus Crataegi 7.5g Monas cuspurpureus Went 3g
Exocarpium Citri Grandis 7.5g Radix Sophorae Flavescentis 7.5g Rhizoma Atractylodis 7.5g Semen Lepidii (Semen Descurainiae) 7.5g
Semen Plantaginis 15g Semen Cassiae 15g
After crude drug adds 3 times of water and is heated to boiling, extract 4h, filter, medicinal residues add 3 times of decoctings and boil 4h, filter, and medicinal residues discard, extracted twice liquid is merged, and 60～65 ℃ are evaporated to D60=1.05-1.10, get concentrated solution, after being cooled to room temperature, add 90% ethanol precipitate with ethanol, the limit edged stirs, to supernatant contain alcohol 70%, leave standstill 12h, filter, be precipitated, namely get pharmaceutically active substance, subsequently, take this material as raw material, and the mixed granulation of starch, ethanol with 95% is made wetting agent, add an amount of magnesium stearate, tabletting obtains tablet.
Embodiment 8
Radix Et Rhizoma Rhei 12g prepared RHIZOMA COPTIDIS with rhizoma zingiberis recens juice 30g Fructus Crataegi 30g Monas cuspurpureus Went 12g
Exocarpium Citri Grandis 30g Radix Sophorae Flavescentis 30g Rhizoma Atractylodis 30g Semen Lepidii (Semen Descurainiae) 30g
Semen Plantaginis 60g Semen Cassiae 60g
Crude drug add 10 times be heated to boiling after, extract 4h, obtain water extraction liquid, repeat to decoct 4 times, the extracting solution that obtains merges, and 60～65 ℃ are evaporated to D60=1.05-1.10, get concentrated solution, be cooled to room temperature after, add 95% ethanol precipitate with ethanol, the limit edged stirs, and contains alcohol 75% to supernatant, leaves standstill 12h, filter, be precipitated, namely get pharmaceutically active substance, subsequently, take this material as raw material, and the mixed granulation of starch, wetting agent made with 95% ethanol, add an amount of magnesium stearate, tabletting obtains tablet.
Embodiment 9
Radix Et Rhizoma Rhei 6g prepared RHIZOMA COPTIDIS with rhizoma zingiberis recens juice 15g Fructus Crataegi 15g Monas cuspurpureus Went 6g Exocarpium Citri Grandis 15g
Radix Sophorae Flavescentis 15g Rhizoma Atractylodis 15g Semen Lepidii (Semen Descurainiae) 15g Semen Plantaginis 30g Semen Cassiae 30g
Crude drug adds 10 times of water soaking 1h, be heated to boiling after, extract 1h, filter, 60～65 ℃ are evaporated to D60=1.05-1.10, get concentrated solution, be cooled to room temperature after, add 95% ethanol precipitate with ethanol, the limit edged stirs, and contains alcohol 75% to supernatant, leaves standstill 12h, filters, be precipitated, namely get pharmaceutically active substance, subsequently, take this material as raw material, and the mixed granulation of starch, wetting agent made with 95% ethanol, add an amount of magnesium stearate, tabletting obtains tablet.
Embodiment 10
Radix Et Rhizoma Rhei 6g prepared RHIZOMA COPTIDIS with rhizoma zingiberis recens juice 15g Fructus Crataegi 15g Monas cuspurpureus Went 6g Exocarpium Citri Grandis 15g
Radix Sophorae Flavescentis 15g Rhizoma Atractylodis 15g Semen Lepidii (Semen Descurainiae) 15g Semen Plantaginis 30g Semen Cassiae 30g
Crude drug adds 8 times of water soaking 0.3h, be heated to boiling after, extract 2h, filter, medicinal residues add 5 times of decoctings and boil 3h, filter, medicinal residues discard, and extracted twice liquid is merged, and 60～65 ℃ are evaporated to D60=1.05-1.10, concentrated solution, be cooled to room temperature after, add 95% ethanol precipitate with ethanol, the limit edged stirs, and contains alcohol 70% to supernatant, leaves standstill 24h, filter, be precipitated, namely get pharmaceutically active substance, subsequently, take this material as raw material, granulate with starch is mixed, make wetting agent with 95% ethanol, add an amount of magnesium stearate, tabletting obtains tablet.
Claims (10)
1. the preparation method of a slimming medicine is characterized in that, described slimming medicine is prepared from by following raw material of Chinese medicine medicine: Radix Et Rhizoma Rhei, prepared RHIZOMA COPTIDIS with rhizoma zingiberis recens juice, Fructus Crataegi, Monas cuspurpureus Went, Exocarpium Citri Grandis, Radix Sophorae Flavescentis, Rhizoma Atractylodis, Semen Lepidii (Semen Descurainiae), Semen Plantaginis, Semen Cassiae, its preparation method are included as water and decoct, with the alcohol precipitation, be processed into the step of pharmaceutical preparation with precipitation as pharmaceutically active substance.
2. according to claim 1 preparation method is characterized in that the proportioning of each raw material of Chinese medicine medicine is as follows:
Radix Et Rhizoma Rhei 3-12 part prepared RHIZOMA COPTIDIS with rhizoma zingiberis recens juice 7.5-30 part Fructus Crataegi 7.5-30 part Monas cuspurpureus Went 3-12 part
Exocarpium Citri Grandis 7.5-30 part Radix Sophorae Flavescentis 7.5-30 part Rhizoma Atractylodis 7.5-30 part Semen Lepidii (Semen Descurainiae) 7.5-30 part
Semen Plantaginis 15-60 part Semen Cassiae 15-60 part.
3. according to claim 1 preparation method is characterized in that the proportioning of each raw material of Chinese medicine medicine is as follows:
Radix Et Rhizoma Rhei 4.5-8 part prepared RHIZOMA COPTIDIS with rhizoma zingiberis recens juice 11.25-20 part Fructus Crataegi 11.25-20 part Monas cuspurpureus Went 4.5-8 part
Exocarpium Citri Grandis 11.25-20 part Radix Sophorae Flavescentis 11.25-20 part Rhizoma Atractylodis 11.25-20 part Semen Lepidii (Semen Descurainiae) 11.25-20 part
Semen Plantaginis 22.5-40 part Semen Cassiae 22.5-40 part.
4. according to claim 1 preparation method is characterized in that the proportioning of each raw material of Chinese medicine medicine is as follows:
15 parts of 6 parts of Exocarpium Citri Grandises of 15 parts of Monas cuspurpureus Went of 15 parts of Fructus Crataegi of 6 parts of prepared RHIZOMA COPTIDIS with rhizoma zingiberis recens juice of Radix Et Rhizoma Rhei
30 parts of 30 parts of Semen Cassiaes of 15 portions of Semen Plantaginiss of 15 parts of Semen Lepidii (Semen Descurainiae)s of 15 parts of Rhizoma Atractylodis of Radix Sophorae Flavescentis.
5. according to claim 1 preparation method is characterized in that described Chinese medicine for losing weight is any pharmaceutically useful dosage form.
6. according to claim 1 preparation method is characterized in that described Chinese medicine for losing weight contains the medicine acceptable carrier.
7. according to claim 1 preparation method is characterized in that described Chinese medicine for losing weight is peroral dosage form.
8. according to claim 1 preparation method, it is characterized in that described Chinese medicine for losing weight is selected from following dosage form: tablet, capsule, oral liquid, suck agent, granule, pill, powder, unguentum, sublimed preparation, suspensoid, powder, injection, suppository, drop pill, spray, drop, patch.
9. the preparation method of claim 1 is characterized in that, the process following steps: crude drug decocts with water 1-5 time, each 1-4 hour, amount of water was 3-10 times of crude drug weight, and decoction liquor is filtered, medicinal residues discard, and are concentrated, add alcohol and make precipitation, filter to get precipitation, namely get pharmaceutically active substance, subsequently, take this material as raw material, add the medicine acceptable carrier when needing, make pharmaceutical preparation according to the routine techniques of galenic pharmacy.
10. according to claim 9 preparation method is characterized in that, through following steps: crude drug adds 10 times of water soaking 0.5h, after being heated to boiling, extract 1h, filter, medicinal residues add 8 times of decoctings and boil 1h, filter, and medicinal residues discard, extracted twice liquid is merged, and 60～65 ℃ are evaporated to D60=1.05-1.10, get concentrated solution, after being cooled to room temperature, add 95% ethanol precipitate with ethanol, the limit edged stirs, and contains alcohol 75% to supernatant, leave standstill 12h, filter, the precipitation oven dry namely gets pharmaceutically active substance, subsequently, take this material as raw material, add the medicine acceptable carrier when needing, make pharmaceutical preparation according to the routine techniques of galenic pharmacy.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110200779.8A CN102885919B (en) | 2011-07-18 | 2011-07-18 | A kind of preparation of slimming medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110200779.8A CN102885919B (en) | 2011-07-18 | 2011-07-18 | A kind of preparation of slimming medicine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102885919A true CN102885919A (en) | 2013-01-23 |
| CN102885919B CN102885919B (en) | 2016-01-27 |
Family
ID=47529737
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201110200779.8A Expired - Fee Related CN102885919B (en) | 2011-07-18 | 2011-07-18 | A kind of preparation of slimming medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102885919B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105078930A (en) * | 2014-05-16 | 2015-11-25 | 北京中卫神农慢性病医学研究院有限公司 | Smoke medicament and preparation method thereof |
| CN105999176A (en) * | 2016-07-07 | 2016-10-12 | 潘秀岳 | Traditional Chinese medicine body slimming paste and preparation method thereof |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1593551A (en) * | 2004-06-25 | 2005-03-16 | 浙江省医学科学院 | Blood fat lowering capsule or tablet and its preparation |
| US20060083797A1 (en) * | 2004-10-18 | 2006-04-20 | Hyung-Min Kim | Alcohol-fermented food or pharmaceutical composition for prevention of obesity and process for preparation thereof |
| CN1762441A (en) * | 2004-10-22 | 2006-04-26 | 山西亚宝药业集团股份有限公司 | Chinese medicine composition for treating hyperlipemia and preparing method thereof |
| CN101406541A (en) * | 2008-09-11 | 2009-04-15 | 牛志刚 | Four-flavor haw thorn granule |
| CN101692895A (en) * | 2009-10-19 | 2010-04-14 | 闫聿逊 | Lipid-lowering health food |
| CN102000185A (en) * | 2010-12-05 | 2011-04-06 | 汪阳 | Formula of Chinese medicament with weight-losing effect |
-
2011
- 2011-07-18 CN CN201110200779.8A patent/CN102885919B/en not_active Expired - Fee Related
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1593551A (en) * | 2004-06-25 | 2005-03-16 | 浙江省医学科学院 | Blood fat lowering capsule or tablet and its preparation |
| US20060083797A1 (en) * | 2004-10-18 | 2006-04-20 | Hyung-Min Kim | Alcohol-fermented food or pharmaceutical composition for prevention of obesity and process for preparation thereof |
| CN1762441A (en) * | 2004-10-22 | 2006-04-26 | 山西亚宝药业集团股份有限公司 | Chinese medicine composition for treating hyperlipemia and preparing method thereof |
| CN101406541A (en) * | 2008-09-11 | 2009-04-15 | 牛志刚 | Four-flavor haw thorn granule |
| CN101692895A (en) * | 2009-10-19 | 2010-04-14 | 闫聿逊 | Lipid-lowering health food |
| CN102000185A (en) * | 2010-12-05 | 2011-04-06 | 汪阳 | Formula of Chinese medicament with weight-losing effect |
Non-Patent Citations (4)
| Title |
|---|
| 仝小林: "《糖尿病中医防治指南解毒》", 31 August 2009, 中国中医药出版社, article "医案", pages: 16 * |
| 刘雪花: "苦参生物碱的药理研究进展", 《中国实用医药》, vol. 4, no. 14, 31 May 2009 (2009-05-31) * |
| 王少华等: "《中西医结合诊治慢性肾功能衰竭》", 31 May 2004, 军事医学科学出版社, article "泻心汤", pages: 204 * |
| 袁学江等: "《中国家庭自诊自疗自养》", 31 January 1999, 内蒙古科学技术出版社, article "专方专药", pages: 161 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105078930A (en) * | 2014-05-16 | 2015-11-25 | 北京中卫神农慢性病医学研究院有限公司 | Smoke medicament and preparation method thereof |
| CN105999176A (en) * | 2016-07-07 | 2016-10-12 | 潘秀岳 | Traditional Chinese medicine body slimming paste and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102885919B (en) | 2016-01-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103041118B (en) | Composition with effects of reducing blood sugar and reducing blood lipid | |
| CN106492110A (en) | A kind of sobering-up composition, the relieving alcoholism and protecting the liver preparation comprising which and its application | |
| CN104606612A (en) | Alcohol-expelling kidney-tonifying tablet candy and preparation method thereof | |
| CN103301412A (en) | Traditional Chinese medicine composition for treating alcoholic liver | |
| CN102600423A (en) | Preparation method of Chinese medicine for treating hepatic fibrosis | |
| CN101953936A (en) | Traditional Chinese medicine preparation for treating immune thrombocytopenia and preparation method thereof | |
| CN106177432A (en) | A kind of health composition comprising leaf of Cyclocarya paliurus Iljinskaja, Folium Mori, green tea and Rhizoma Polygonati Odorati | |
| CN102885919B (en) | A kind of preparation of slimming medicine | |
| CN102106965A (en) | Composition for treating acute injury of soft tissue and application thereof | |
| CN102048841B (en) | Lactogenic traditional Chinese medicine composition and preparation method thereof | |
| CN102048890B (en) | Traditional Chinese medicine composition with galactagogue effect and preparation method thereof | |
| CN101283761A (en) | Smallanthus sonchifolius fruit extract and extracting method and application | |
| CN102784230B (en) | Pharmaceutical composition preparation for treating nutritional anemia | |
| CN102274346B (en) | Medicament or health food composition for preventing hypertension and preparation method and purpose thereof | |
| CN102885921B (en) | A kind of Chinese medicine composition for losing weight | |
| CN102885918B (en) | A kind of preparation method of weight-reducing Chinese medicinal preparation | |
| CN104623097A (en) | Application of Pu'er tea extract in preparation of fat reducing medicines or health foods | |
| CN103272146A (en) | Medicine composition used for preventing and treating alcoholic fatty liver and preparation method thereof | |
| CN104337920A (en) | Traditional Chinese medicine composition for improving sleep quality | |
| CN101745042B (en) | Composition with effects of relieving alcoholism and protecting liver and preparation method thereof | |
| CN107233491A (en) | It is a kind of to improve the antifatigue maca composition of energy | |
| CN102885922B (en) | A kind of preparation method of slimming medicine | |
| CN102599312B (en) | Oligosaccharide Panax notoginseng sweet tea and preparation method thereof | |
| CN102885923B (en) | A kind of preparation method of Chinese medicine for losing weight | |
| CN102885920B (en) | A kind of Chinese medicine preparation compositions for losing weight |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CP03 | Change of name, title or address | ||
| CP03 | Change of name, title or address |
Address after: 300410 Tianjin city Beichen District Huaihe road and road intersection Dingjiang tianzhijiao Park forensic Center for Intellectual Property Department Patentee after: Tasly Pharmaceutical Group Limited by Share Ltd Address before: 300410 Tianjin City Hedong District of Beichen Puji Road No. 2 city of the modern Chinese Medicine Patentee before: Tasly Pharmaceutical Group Co., Ltd. |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160127 Termination date: 20210718 |